

**THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-78. Cancelled.

79. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising

- (a) an osteogenic protein;
- (b) an injectable hyaluronic acid ester; and
- (c) a pore former selected from a liquid pore former or sodium bicarbonate,

wherein the composition is injectable through the skin of a patient.

80. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising

- (a) an osteogenic protein;
- (b) an injectable hyaluronic acid ester; and
- (c) a pore former selected from a liquid pore former or sodium bicarbonate,

wherein the composition is injectable through the skin of a patient, and upon injection the osteogenic protein and hyaluronic acid ester form a porous precipitate.

81. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising

- (a) an osteogenic protein;
- (b) an injectable hyaluronic acid ester; and

(c) a pore former selected from a liquid pore former or sodium bicarbonate,  
wherein the composition is injectable through the skin of a patient, and upon injection the pore former is extracted from the osteogenic protein and hyaluronic acid ester by solubilization in situ.

82. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid ester is at least 50% esterified.

83. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid ester is at least 60% esterified.

84. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid is at least 65% esterified.

85. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid is at least 75% esterified.

86. The composition of any one of claims 79 to 81, wherein the hyaluronic acid is at least 80% esterified.

87. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid is 100% esterified.

88. (New) The composition of any one of claims 79 to 81, wherein the liquid pore former is polyethylene glycol.

89. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid ester is solubilized in an organic solvent.

90. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid ester is solubilized in an aqueous buffer.

91. (New) The composition of any one of claims 79 to 81, further comprising TCP.

92. (New) The composition of any one of claims 79 to 81, wherein the osteogenic protein is selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12.

93. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid ester is Hyaff11.

94. (New) The composition of claim 93, wherein the liquid pore former is polyethylene glycol.

95. (New) The composition of claim 93, wherein the hyaluronic acid ester is solubilized in an organic solvent.

96. (New) The composition of claim 93, further comprising TCP.

97. (New) The composition of claim 93, wherein the osteogenic protein is selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12.

98. (New) The composition of any one of claims 79 to 81, wherein the hyaluronic acid ester is Hyaff11p80.

99. (New) The composition of claim 98, wherein the liquid pore former is polyethylene glycol.

100. (New) The composition of claim 98, wherein the hyaluronic acid ester is solubilized in an organic solvent.

101. (New) The composition of claim 98, further comprising TCP.

102. (New) The composition of claim 98, wherein the osteogenic protein is selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12.

103. (New) A composition for delivery of osteogenic proteins to a patient comprising an osteogenic protein and Hyaff11p65, wherein the composition is injectable through the skin of the patient.

104. (New) The composition of claim 103, wherein the osteogenic protein is selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12.

105. (New) The composition of claim 103, wherein the Hyaff11p65 is solubilized in aqueous buffer.

106. (New) The composition of claim 103, further comprising TCP.

107. (New) A composition for delivery of osteogenic proteins to a patient comprising BMP-12 and Hyaff11p65, wherein the composition is injectable through the skin of the patient.